

Issue of Warrants and Change to Lease Agreement

28 Feb 2019

REDX PHARMA PLC

(“Redx” or “the Company”)

Alderley Park, 28 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, as previously noted in its 2018 Annual Report, it has successfully completed an agreement with Alderley Park Limited to significantly reduce its accommodation footprint in the Company’s Headquarters at Alderley Park, Cheshire.

As part of the agreement, on 27 February 2019, a Warrant to acquire 750,000 ordinary shares of 1p each in the share capital of the Company was issued to Alderley Park Limited as follows:

The subscription price payable per warrant share on exercise of the warrant is:

Price	No. of Shares	Date of Vesting
13.75p	125,000	27 February 2019
20p	125,000	27 February 2019
27p	125,000	27 February 2020
35p	125,000	27 February 2020
42.5p	125,000	27 February 2021
50p	125,000	27 February 2021

The Warrant will not become exercisable until the second anniversary of issue.

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469
920

Lisa Anson, Chief Executive Officer

Cantor Fitzgerald Europe (Nominated Advisor & Joint
Broker)

T: +44 20 7894
7000

Phil Davies

WG Partners LLP (Joint Broker)

T: +44 20 3705
9330

Claes Spång/ Chris Lee/ David Wilson

FTI Consulting

T: +44 20 3727
1000

Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc

Redx is a UK based biotechnology company whose shares are traded on AIM ([AIM:REDX](#)). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

If you would like to sign up to regular alerts from Redx Pharma, please follow this link <https://www.redxpharma.com/investors/email-alerts/>